A.P. Pharma to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12
11/03/2008
|
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 3, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that Ronald J. Prentki, the Company's president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, on Wednesday, November 12, 2008, at 10:20 a.m. Eastern time at The Palace Hotel in New York City.
Interested parties can access a live audio webcast at www.appharma.com. An archived presentation will be available on the Company's Web site for 14 days.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). A.P. Pharma's lead product, APF530, is being developed for the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is delivered by a single subcutaneous injection and contains the 5HT3 antagonist granisetron. APF530 has successfully completed Phase 3 trials and the company plans to file the NDA in December 2008. Initial target areas of application for the company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications. For further information visit the company's Web site at www.appharma.com.
CONTACT: Investor Relations Contacts:
Lippert/Heilshorn & Associates
Don Markley (dmarkley@lhai.com)
(310) 691-7100
or
Company Contacts:
A.P. Pharma, Inc.
Ronald Prentki
President & Chief Executive Officer
(650) 366-2626
SOURCE: A.P. Pharma, Inc.